(Q27025513)

language of work or name

1 reference

February 2015

1 reference

published in

Gastroenterology report

1 reference

volume

3

1 reference

issue

1

1 reference

page(s)

63-8

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Epidemiology and natural history of inflammatory bowel diseases

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Have biologics changed the natural history of Crohn's disease?

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Treatment algorithms in Crohn's - up, down or something else?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Abdominal pain in ulcerative colitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn's disease

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Clinical, serological and genetic predictors of inflammatory bowel disease course

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324872

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Restaurantmanhaj's

31 May 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FGASTRO%2FGOU087

A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker P

21 January 2018

1 reference

12 December 2020

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

1 reference

12 December 2020

Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease

1 reference

12 December 2020

Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease

1 reference

12 December 2020

A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2012May 19-22, 2012 • San Diego, CaliforniaSpecial Reporting on:• Novel Infliximab and Antibody-to-lnfliximab Assays Are Predictive of Dise

1 reference

12 December 2020

The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD

1 reference

12 December 2020

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

12 December 2020

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

1 reference

12 December 2020

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

1 reference

12 December 2020

Immunological mechanism underlying the immune response to recombinant human protein therapeutics

1 reference

12 December 2020

Identifiers

DOI

10.1093/GASTRO/GOU087

0 references

1 reference

PubMed publication ID

25567472

1 reference